KKR is poised to generate just over 3x its money through its sale of U.K. life science tools company LGC Group, according to a source familiar with the matter. Four years into its investment, the buyout firm said Thursday it agreed to sell LGC to European private equity groups Cinven and Astorg. Financial terms of the transaction weren’t disclosed; however, this source and a second said the deal assigns LGC a value of approximately 3 billion pounds ($3.9 billion). The valuation implies an Ebitda multiple just over 20x, one of the sources said.